Reunion Neuroscience (REUN) Stock

Patient Enrollment Ongoing in Phase 2 RECONNECT Trial of RE104 in Postpartum Depression (PPD); Topline Data Anticipated Mid-2025

MORRISTOWN, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic therapeutic solutions, presented a poster detailing RE104 Phase 1 data at the American College of Neuropsychopharmacology (ACNP) 63rd Annual Meeting in Phoenix, Arizona.

MORRISTOWN, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychedelic therapeutic solutions, today announced the appointment of Mark Pollack, M.D., as Chief Medical Officer. Dr. Pollack previously served as a member of Reunion's Advisory Board and is a highly accomplished psychiatrist with decades of leadership experience in neuroscience-focused drug development and clinical research. Pollack replaces Dr. Robert Alexander who will continue to remain involved with Reunion as a strategic advisor.

Initiative Coincides with Start of Reunion's Phase 2 RECONNECT Study in Postpartum Depression Initiative Coincides with Start of Reunion's Phase 2 RECONNECT Study in Postpartum Depression

Reunion Neuroscience Inc Thursday reported a net loss of $48,492,996 for its fiscal year 2023, even as the company remains upbeat on the development of its psychedelic treatment for postpartum depression. Reunion, formerly known as Field Trip Health & Wellness Ltd, will be going private during the third quarter of this year after agreeing to be acquired by biotechnology investment firm MPM BioImpact for about US$13.1 million, or US$1.12 per share in cash.